Remsima
Remsima, a drug containing infliximab used to treat conditions like rheumatoid arthritis, Crohn's disease, and psoriasis, is being recalled across the European Union due to a newly identified contraindication. This means the drug has been found to be unsafe for certain patients who were previously thought to be able to use it. The recall affects all patients in the EU who are currently taking or may have been prescribed this medication.
- Product
- Active substances: infliximab. Therapeutic area: Arthritis, Psoriatic;Spondylitis, Ankylosing;Colitis, Ulcerative;Psoriasis;Crohn Disease;Arthritis, Rheumatoid. ATC code: L04AB02
- Reason
- New contraindication
- Classification
- Class II
- Category
- drug recall
- Country
- European Union
- Agency
- EMA-DHPC
- Recall date
- 2025-12-08
- Status
- Ongoing
- Distribution
- European Union
Official recall notice from EMA-DHPC
Recall details on Nibble Recalls: https://trynibble.app/recalls/086e7437-4ffb-49ad-a04f-79e477249db2